4DMedical Accelerates US Adoption with UC San Diego Health

About 4DMedical Limited

4DMedical Limited (ASX: 4DX) is an Australian medical technology company focused on transforming the diagnosis and management of respiratory disease through advanced imaging and artificial intelligence. Headquartered in Melbourne with a growing U.S. presence in California, the company develops software solutions that convert standard medical imaging into detailed functional insights, enabling earlier detection and more precise monitoring of lung disease.

Listed on the ASX, 4DMedical has built a differentiated portfolio around its patented XV Technology, which underpins products including XV Lung Ventilation Analysis Software, CT LVA and its most recent innovation, CT:VQ. Following U.S. Food and Drug Administration clearance in August 2025, CT:VQ has emerged as a potentially disruptive alternative to traditional ventilation–perfusion imaging, positioning 4DMedical at the forefront of functional lung diagnostics. The adoption of CT:VQ by UC San Diego Health marks another step in the company’s transition from development to commercial execution in one of the world’s largest healthcare markets.

UC San Diego Health Deployment

UC San Diego Health has entered into a commercial arrangement to commence clinical use of CT:VQ, becoming the fourth major U.S. academic medical centre to deploy the technology. Consistently ranked among the top 10 U.S. institutions for pulmonology and lung surgery, UCSD is recognised globally for clinical excellence and imaging innovation.

The deployment follows a structured launch framework, with introductory pricing in place until 31 March 2026 to support workflow integration and early clinical adoption before transitioning to full commercial terms. The program is led by Dr Jonathan Chung, Chief of the Division of Cardiothoracic Imaging and Professor of Radiology, whose department is internationally regarded for pioneering advanced imaging techniques.

UCSD joins Stanford University, the University of Miami and Cleveland Clinic as reference sites for CT:VQ, creating a network of elite institutions that underpin 4DMedical’s U.S. commercialisation strategy.

Accelerating Adoption Following FDA Clearance

The pace of adoption highlights the strength of 4DMedical’s go-to-market approach. In just over four months since FDA clearance, CT:VQ has been deployed at four of the most respected academic medical centres in the United States. These early adopters serve as influential opinion leaders in cardiothoracic imaging, supporting physician education, clinical validation and broader awareness of the technology.

Such rapid uptake is notable in the context of U.S. healthcare, where new imaging technologies often face long adoption cycles. Management has attributed this momentum to CT:VQ’s ability to integrate seamlessly into existing CT workflows while delivering clinically meaningful functional insights that go beyond structural assessment alone.

Clinical and Operational Advantages of CT:VQ

CT:VQ is the first imaging solution globally capable of generating quantitative ventilation–perfusion maps from a routine, non-contrast CT scan. By analysing subtle lung motion and density changes, the software provides detailed visualisation of airflow and blood flow distribution within the lungs.

Unlike traditional nuclear medicine VQ scans, CT:VQ requires no radiotracers, no contrast agents, no specialised nuclear facilities and no additional scanners. This significantly reduces operational complexity, regulatory burden and scheduling delays for hospitals. Clinically, the technology delivers higher spatial resolution and quantitative reporting, supporting more sensitive and specific diagnosis across a range of respiratory conditions.

The ability to deploy CT:VQ using existing CT infrastructure also enables adoption beyond tertiary hospitals into community and regional settings, potentially broadening access to advanced lung diagnostics across the healthcare system.

Strategic Importance of Reference Sites

Establishing CT:VQ at prestigious academic medical centres is central to 4DMedical’s commercialisation strategy. These institutions act as reference sites, influencing broader clinical practice and supporting reimbursement acceptance over time.

Academic centres such as UCSD not only validate the clinical utility of new technologies but also play a key role in training radiologists and shaping future standards of care. As adoption expands, management expects these reference sites to accelerate uptake across affiliated hospital networks and private healthcare providers.

Technology Platform and Portfolio Expansion

CT:VQ builds on 4DMedical’s broader software portfolio, which leverages artificial intelligence and advanced image analysis to extract functional insights from standard imaging. The company’s acquisition of Imbio in 2023 added AI-driven analytics capabilities, further enhancing its ability to quantify lung structure and function.

Delivered through a software-as-a-service model, 4DMedical’s solutions integrate into existing hospital IT systems, supporting scalability and recurring revenue. This model aligns with broader healthcare digitisation trends, as providers seek cloud-enabled solutions that improve productivity and patient outcomes without major capital investment.

Industry Context and Market Opportunity

Respiratory disease remains a leading cause of morbidity globally, with conditions such as pulmonary embolism, chronic obstructive pulmonary disease and post-surgical lung complications placing significant strain on healthcare systems. Demand for earlier, more accurate diagnosis continues to grow, particularly as populations age.

At the same time, healthcare providers face pressure to reduce costs, streamline workflows and improve patient throughput. Technologies that can replace or augment complex legacy procedures while delivering superior clinical information are increasingly attractive. CT:VQ addresses these needs directly, positioning 4DMedical within a large and expanding market for advanced diagnostic imaging.

Outlook

Following the UC San Diego Health deployment, 4DMedical enters 2026 with increasing commercial traction in the United States. Management has indicated that further institutional deployments are under discussion, supported by growing awareness among pulmonologists and radiologists.

While early arrangements include introductory pricing, the transition to full commercial terms is expected to support revenue growth as utilisation increases. Continued execution across reference sites, reimbursement pathways and clinical evidence generation will be key to sustaining momentum.

Conclusion

The adoption of CT:VQ by UC San Diego Health represents another significant milestone for 4DMedical, reinforcing rapid post-FDA clearance uptake among elite U.S. academic medical centres. With four major deployments achieved in just four months, the company has demonstrated both the clinical relevance of its technology and the effectiveness of its commercial strategy. As functional lung imaging evolves toward becoming a new standard of care, 4DMedical is increasingly positioned as a leader in next-generation respiratory diagnostics.